

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. Cancelled
2. (Currently amended) ~~Isolated EM 1, comprising a mutated endostatin protein,~~ An isolated polypeptide the amino acid sequence of which comprises residues 168-175 and a deletion mutation of an endostatin protein of SEQ ID NO:2, wherein the deletion mutation comprises consists of a deletion of nine consecutive amino acids from the C-terminus of the endostatin protein, and wherein the isolated EM 1 is characterized as having polypeptide has anti-angiogenic activity.
3. Cancelled
4. (Currently amended) The isolated ~~EM 1 polypeptide~~ of Claim 2, wherein the ~~deletion of nine consecutive amino acids comprises~~ have the sequence set forth in SEQ ID NO: 25.

Claims 5-10 are withdrawn from consideration.

11. (Currently amended) A fusion protein, comprising ~~two or more protein molecules, and further comprising the EM 1~~ the isolated polypeptide of Claim 3 ~~2~~.
12. (Previously amended) The fusion protein of Claim 11, further comprising at least one protein molecule selected from the group consisting of: restin, endostatin, angiostatin, apomigren, and EM 1.
13. (Currently amended) A composition comprising, as a biologically active ingredient, the ~~EM 1~~ polypeptide of Claim 3 ~~2~~.
14. (Currently amended) The composition of Claim 13, and a ~~pharmaceutically compatible~~ pharmaceutically compatible carrier.

15. (Original) A composition comprising, as a biologically active ingredient, the fusion protein of Claim 11.

16. (Original) A composition comprising, as a biologically active ingredient, the fusion protein of Claim 12.

Claims 17-34 are withdrawn from consideration.

35. Cancelled

36. (New) A protein consisting of amino acids 1-175 of SEQ ID NO:2.